On 31 January 2008, orphan designation EU/3/07/526 was granted by the European Commission to Pharmion Ltd, United Kingdom, for N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in November 2008 and subsequently to CanReg (Europe) Limited, Ireland, in March 2009.
In November 2015, CanReg (Europe) Limited changed name to Mapi Ireland Limited.
- What is acute myeloid leukaemia?
Acute myeloid leukaemia is a disease in which cancer cells are found in the blood and the bone marrow. The bone marrow is the spongy tissue inside the large bones in the body. Normally, the bone marrow makes cells called “blasts” that mature into several different types of blood cells that have specific functions in the body. These include red cells, white cells and platelets. Red blood cells carry oxygen and other materials to all tissues of the body. White blood cells fight infection. Platelets make the blood clot. When leukaemia develops, the bone marrow produces large numbers of abnormal blood cells. There are several types of leukaemias. In myeloid leukaemia blasts that are developing into white blood cells called granulocytes are affected. These blasts do not mature but multiply abnormally and accumulate in the bone marrow. Then, they are also found in the blood. Leukaemia can be acute (when it develops quickly with many blasts). Acute myeloid leukaemia is life-threatening.
- What is the estimated number of patients affected by the condition?
At the time of designation, acute myeloid leukaemia affected less than 2.4 people in 10,000 per year in the European Union (EU)*. This is equivalent to a total of fewer than 120,000 people per year, which was considered to be below the threshold for orphan designation. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 498,000,000 (Eurostat 2006).
- What treatment are available?
Treatment for leukaemia is complex and depends on a number of factors including the type of leukaemia, the extent of the disease and whether the leukaemia has been treated before. It also depends on the age, the symptoms, and the general health of the patient. The primary treatment of acute myeloid leukemia is chemotherapy (using drugs to kill cancer cells). Several products were authorised for the condition in the Community at the time of submission of the application for orphan drug designation. N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide might be of potential significant benefit for the treatment of acute myeloid leukaemia. The assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- How is this medicine expected to work?
The genetic material of cells (DNA) is normally tightly bound around structures called histones. When histones are acetylated (a specific chemical status) the effect of this on DNA is that its information cannot be accessible for protein synthesis. N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide appears to block the activity of an enzyme, called histone deacetylase. Inhibition of the histone deacetylases has been linked to a decrease in multiplication of tumour cells and suppression of some tumours.
- What is the stage of development of this medicine?
The effects of N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide were evaluated in experimental models. At the time of submission of the application for orphan designation, clinical trials in patients with acute myeloid leukaemia were ongoing.
N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide has received orphan designation in the European Union for treatment of Hodgkin’s lymphoma on 14 September 2007. Orphan drug designation was granted in the United States for the treatment of Hodgkin’s lymphoma.
According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 5 December 2007 a positive opinion recommending the grant of the above-mentioned designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/07/526: Public summary of positive opinion for orphan designation of N- (2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide for the treatment of acute myeloid leukaemia||(English only)||2009-09-23|
|Active substance||N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide|
|Disease/condition||Treatment of acute myeloid leukemia|
|Date of decision||30/01/2008|
|Orphan decision number||EU/3/07/526|
Review of designation
Sponsor’s contact details
Mapi Ireland Limited
Tel. +353 42 937 67 40
Fax +353 42 937 67 40
E-mail : email@example.com
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.